Next-Generation Sequencing for BCR-ABL Mutations in Patients Receiving First- and Second-Line Tyrosine Kinase Inhibitors for CML


Next-Generation Sequencing for BCR-ABL Mutations in Patients Receiving First- and Second-Line Tyrosine Kinase Inhibitors for CML
Slides from a presentation at ASH 2015

Soverini S et al. BCR-ABL mutations in chronic myeloid leukemia (CML) patients (pts) with failure and warning to first- and second-line tyrosine kinase inhibitor (TKI) therapy: What is the advantage of next-generation sequencing (NGS) over conventional sequencing? Proc ASH 2015;Abstract 346.